Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
35.35 USD | +4.68% | +17.04% | +80.39% |
Apr. 29 | Leerink Partners Starts Neurogene With Outperform Rating, $46 Price Target | MT |
Mar. 22 | North American Morning Briefing : Stocks Struggle After New Records | DJ |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 434M |
---|---|---|---|---|---|
Net income 2024 * | -66M | Net income 2025 * | -74M | EV / Sales 2024 * | - |
Net cash position 2024 * | 327M | Net cash position 2025 * | 501M | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-8.75
x | P/E ratio 2025 * |
-9.32
x | Employees | 91 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 86.65% |
Latest transcript on Neurogene Inc.
1 day | +2.59% | ||
1 week | +14.60% | ||
Current month | -0.73% | ||
1 month | -23.23% | ||
3 months | +10.53% | ||
Current year | +76.63% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-02 | 34.87 | +3.26% | 54 340 |
24-05-01 | 33.77 | -2.06% | 61,261 |
24-04-30 | 34.48 | +3.23% | 155,575 |
24-04-29 | 33.4 | +11.48% | 121,085 |
24-04-26 | 29.96 | +0.30% | 47,839 |
Delayed Quote Nasdaq, May 02, 2024 at 11:34 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+76.63% | 434M | |
+19.04% | 42.68B | |
-3.08% | 42.4B | |
+45.32% | 40.04B | |
-6.20% | 28.31B | |
+7.11% | 24.94B | |
-20.59% | 18.96B | |
+30.21% | 12.3B | |
-2.55% | 11.95B | |
-2.89% | 11.55B |
- Stock Market
- Equities
- NGNE Stock